CN110996994A - 加强免疫应答的方法 - Google Patents

加强免疫应答的方法 Download PDF

Info

Publication number
CN110996994A
CN110996994A CN201880052580.5A CN201880052580A CN110996994A CN 110996994 A CN110996994 A CN 110996994A CN 201880052580 A CN201880052580 A CN 201880052580A CN 110996994 A CN110996994 A CN 110996994A
Authority
CN
China
Prior art keywords
seq
uspa2
protein
immunogenic composition
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880052580.5A
Other languages
English (en)
Chinese (zh)
Inventor
A.K.阿罗拉
V.韦南茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Publication of CN110996994A publication Critical patent/CN110996994A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880052580.5A 2017-08-14 2018-08-13 加强免疫应答的方法 Pending CN110996994A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762545010P 2017-08-14 2017-08-14
US62/545010 2017-08-14
US201862633263P 2018-02-21 2018-02-21
US62/633263 2018-02-21
PCT/EP2018/071860 WO2019034575A1 (en) 2017-08-14 2018-08-13 Methods of boosting immune responses

Publications (1)

Publication Number Publication Date
CN110996994A true CN110996994A (zh) 2020-04-10

Family

ID=63350516

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880052580.5A Pending CN110996994A (zh) 2017-08-14 2018-08-13 加强免疫应答的方法

Country Status (8)

Country Link
US (1) US11723966B2 (enExample)
EP (1) EP3641808A1 (enExample)
JP (2) JP2020530478A (enExample)
CN (1) CN110996994A (enExample)
BR (1) BR112020001768A2 (enExample)
CA (1) CA3072018A1 (enExample)
MX (1) MX2020001820A (enExample)
WO (1) WO2019034575A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543264A (ja) * 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインｄポリペプチドを含む組成物を調製するプロセス
EP4294433A1 (en) * 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
WO2023194971A2 (en) * 2022-04-08 2023-10-12 St. Jude Children's Research Hospital Immunogenic compositions and methods for reducing transmission of pathogens

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071774A1 (en) * 1990-05-31 2007-03-29 Arne Forsgren Protein D - an IgD-binding protein of Haemophilus influenzae
US20100062027A1 (en) * 2005-08-10 2010-03-11 Arne Forsgren Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
WO2012139225A1 (en) * 2011-04-13 2012-10-18 Glaxosmithkline Biologicals S.A. Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
WO2015125118A1 (en) * 2014-02-24 2015-08-27 Glaxosmithkline Biologicals Sa Uspa2 protein constructs and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DE69740108D1 (de) * 1996-12-20 2011-03-10 Univ Texas Moraxella catarrhalis antigene uspa1 und uspa2
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
EP2292632A3 (en) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
MX2008009280A (es) 2006-01-17 2008-12-12 Arne Forsgren Una nueva proteina de haemophilus influenzae expuesta en la superficie (proteina e; pe).

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070071774A1 (en) * 1990-05-31 2007-03-29 Arne Forsgren Protein D - an IgD-binding protein of Haemophilus influenzae
US20100062027A1 (en) * 2005-08-10 2010-03-11 Arne Forsgren Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system
WO2012139225A1 (en) * 2011-04-13 2012-10-18 Glaxosmithkline Biologicals S.A. Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
WO2015125118A1 (en) * 2014-02-24 2015-08-27 Glaxosmithkline Biologicals Sa Uspa2 protein constructs and uses thereof
US20170008932A1 (en) * 2014-02-24 2017-01-12 Glaxosmithkline Biologicals Sa Uspa2 protein constructs and uses thereof

Also Published As

Publication number Publication date
CA3072018A1 (en) 2019-02-21
EP3641808A1 (en) 2020-04-29
US11723966B2 (en) 2023-08-15
WO2019034575A1 (en) 2019-02-21
JP2020530478A (ja) 2020-10-22
MX2020001820A (es) 2020-03-20
US20200197504A1 (en) 2020-06-25
BR112020001768A2 (pt) 2020-09-29
JP2023103380A (ja) 2023-07-26

Similar Documents

Publication Publication Date Title
JP6126993B2 (ja) 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対するワクチン及び組成物
JP2023103380A (ja) 免疫応答を強化する方法
CN103068838B (zh) 基于重组蛋白的抗链球菌感染疫苗
MX2012000158A (es) Vacunas y composiciones contra streptococcus pneumoniae.
CN106061995A (zh) Uspa2蛋白质构建体及其用途
JP2010172332A (ja) Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン
JP6243367B2 (ja) 分類不能（ｎｏｎ−ｔｙｐｅａｂｌｅ）インフルエンザ菌（Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ）ワクチンおよびその使用
JP2009500037A5 (enExample)
JP2015513314A (ja) ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物
CN103501808A (zh) 用于针对肺炎链球菌免疫的组合物
He et al. Recombinant Mip-PilE-FlaA dominant epitopes vaccine candidate against Legionella pneumophila
AU2008226340B2 (en) Treatment or prophylaxis of asthma
AU2018271316B2 (en) A vaccine for treatment or prevention of burkholderia infection in a mammal
US20240148849A1 (en) Immunogenic composition, use and methods
WO2010032139A1 (en) Bacterial and fungal vaccines for the treatment of asthma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200410